Q-omics provides the consensus-scored MYCBP2 profile across patient tissues and cancer cell-line models. MYCBP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYCBP2 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, MYCBP2 protein abundance shows 21,211 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where MYCBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYCBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYCBP2 survival associations across molecular data types. MYCBP2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYCBP2 RNA expression–survival associations across cancer types. High MYCBP2 expression shows unfavorable associations in UVM, but favorable associations in KIRC, HNSC, LGG, SCLC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYCBP2 RNA expression.
This table summarizes MYCBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYCBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYCBP2 shows lower tumor expression in THCA, UCEC, BRCA and KICH and higher tumor expression in CHOL and COAD. The THCA box plot shows higher MYCBP2 RNA expression in normal versus tumor tissue (log2 FC = −0.697, t-test p < 0.001).
This table shows molecular features associated with MYCBP2 in patient tissues and cancer cell lines. In patient samples, MYCBP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYCBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
